Iovance Biotherapeutics, Inc. (0JDK.L) LSE

Currency In USD

AD

Valuation

Market Cap1B
Enterprise Value931.33M
P/E Ratio-11.84
PEG Ratio-0.2
Price/Sales Ratio11.39
Price/Book Ratio5.07
Enterprise/Revenue11.19
Enterprise/EBITDA-13.84

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.89
Operating Margin-0.93
AD

Management Effectiveness

Return On Assets-0.32
Return On Equity-0.41

Income Statement

Revenue263.5M
Revenue/Share0.72
Gross Profit54.38M
EBITDA-362.27M
Net Income-390.98M
Diluted EPS-1.09

Balance Sheet

Total Cash297.67M
Total Cash/Share0.66
Total Debt46M
Total Debt/Equity0.06
Current Ratio4.35
Book Value Per Share1.63

Price History

52-Week Change232.26
52-Week High18.31
52-Week Low3.22
Moving Average 50 Days11.04
Moving Average 200 Days7.44

Statistics

Average Volume53,275
Shares Outstanding381.32M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD